Dimensional Fund Advisors
TCRX icon

Dimensional Fund Advisors’s TScan Therapeutics TCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.8K Sell
65,335
-9,132
-12% -$9.76K ﹤0.01% 3156
2025
Q4 		$74.5K Sell
74,467
-12,849
-15% -$18.6K ﹤0.01% 3184
2025
Q3 		$159K Sell
87,316
-42,540
-33% -$75.4K ﹤0.01% 3148
2025
Q2 		$188K Sell
129,856
-140,243
-52% -$203K ﹤0.01% 3123
2025
Q1 		$373K Sell
270,099
-9,929
-4% -$21.5K ﹤0.01% 3038
2024
Q4 		$851K Buy
280,028
+145,731
+109% +$661K ﹤0.01% 2949
2024
Q3 		$669K Buy
134,297
+122,415
+1,030% +$739K ﹤0.01% 2980
2024
Q2 		$70.5K Buy
+11,882
New +$93.6K ﹤0.01% 3284

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Dimensional Fund Advisors's TCRX Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its TScan Therapeutics (TCRX) stake by 12% in Q1 2026, selling an estimated $9.76K and leaving 65,335 shares worth $65.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3156.

Dimensional Fund Advisors first reported a position in TCRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $851K in Q4 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Dimensional Fund Advisors held 65,335 shares of TScan Therapeutics worth $65.8K as of Q1 2026.
  • Dimensional Fund Advisors sold 9,132 TScan Therapeutics shares in Q1 2026, an estimated $9.76K.
  • TScan Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #3156 holding.
  • Dimensional Fund Advisors first reported a position in TScan Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Dimensional Fund Advisors's TScan Therapeutics position peaked at $851K in Q4 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.